COMPLETE GENOMICS INC

Form 4

November 16, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

burden hours per response...

Estimated average 0.5

Check this box

if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Washington, D.C. 20549

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * OVP VENTURE PARTNERS VI LP

(First)

(Middle)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

COMPLETE GENOMICS INC [GNOM]

(Check all applicable)

Director _X__ 10% Owner

3. Date of Earliest Transaction (Month/Day/Year)

11/16/2010

Officer (give title __ Other (specify below)

C/O OVP VENTURE PARTNERS, 1010 MARKET STREET

(Last)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

KIRKLAND, WA 98033

(City)	(State) (S	Zip) Table	e I - Non-D	Derivative Securities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	(A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value \$0.001	11/16/2010		C	6,313 А 🗓	6,313	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010		С	5,150 A (3)	11,463	I	See Footnote (6)
Common Stock, par	11/16/2010		С	3,535 A (4)	14,998	I	See Footnote

Edgar Filing: COMPLETE GENOMICS INC - Form 4

value \$0.001								<u>(6)</u>
Common Stock, par value \$0.001	11/16/2010	С	9,477	A	<u>(5)</u>	24,475	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	С	4,767	A	<u>(5)</u>	29,242	I	See Footnote
Common Stock, par value \$0.001	11/16/2010	X	3,134	A	\$ 1.5	32,376	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	523	D	\$9	31,853	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	X	647	A	\$ 7.56	32,500	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	544	D	\$9	31,956	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	X	690	A	\$ 7.56	32,646	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	580	D	\$9	32,066	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	X	79	A	\$ 7.56	32,145	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	67	D	\$9	32,078	I	See Footnote (6)
Common Stock, par value	11/16/2010	X	7	A	\$ 7.56	32,085	I	See Footnote (6)

Edgar Filing: COMPLETE GENOMICS INC - Form 4

\$0.001

varue	11/16/2010	F	6	D	\$9	32,079	I	See Footnote
\$0.001								

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of tiorDerivative Securities) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(Α) (Γ	D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to Purchase Series D Preferred Stock (5)	\$ 7.56	11/16/2010		X	31,7	717	<u>(9)</u>	02/13/2014	Common Stock	31,717
Warrant to Purchase Series D Preferred Stock (5)	\$ 7.56	11/16/2010		X	64	1 7	<u>(9)</u>	02/13/2014	Common Stock	647
Warrant to Purchase Series D Preferred Stock (5)	\$ 7.56	11/16/2010		X	33,8	832	<u>(9)</u>	04/06/2014	Common Stock	33,832
Warrant to Purchase Series D	\$ 7.56	11/16/2010		X	69	90	<u>(9)</u>	04/06/2014	Common Stock	690

Preferred Stock (5)								
Warrant to Purchase Series D Preferred Stock (5)	\$ 7.56	11/16/2010	X	11,258	<u>(9)</u>	06/12/2014	Common Stock	11,258
Warrant to Purchase Series D Preferred Stock (5)	\$ 7.56	11/16/2010	X	79	(9)	06/12/2014	Common Stock	79
Warrant to Purchase Series D Preferred Stock (5)	\$ 7.56	11/16/2010	X	1,088	<u>(9)</u>	08/05/2014	Common Stock	1,088
Warrant to Purchase Series D Preferred Stock (5)	\$ 7.56	11/16/2010	X	7	<u>(9)</u>	08/05/2014	Common Stock	7

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
OVP VENTURE PARTNERS VI LP							
C/O OVP VENTURE PARTNERS		X					
1010 MARKET STREET KIRKLAND, WA 98033							
,							
OVP VI ENTREPRENEURS FUND LP		37					
1010 MARKET STREET		X					
KIRKLAND, WA 98033							

Signatures

/s/ Charles P. Waite, Jr., Managing Member, OVP Venture Partners VI, L.P.				
**Signature of Reporting Person	Date			
/s/ Charles P. Waite, Jr., Managing Member, OVP VI Entrepreneurs Fund, L.P.	11/16/2010			

Reporting Owners 4

Edgar Filing: COMPLETE GENOMICS INC - Form 4

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each share of Series A Preferred Stock was automatically converted into common stock immediately prior to the completion of the

 (1) Issuer's initial public offering. Shares are reported on an "as converted" basis giving effect to the 4.615101 conversion ratio applicable to such shares.
- Each share of Series C Preferred Stock was automatically converted into common stock immediately prior to the completion of the (3) Issuer's initial public offering. Shares are reported on an "as converted" basis giving effect to the 8.241076 conversion ratio applicable to such shares.
- (4) Each share of Series D and Series E Preferred Stock was automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering.
- (5) The Exercise Price of the Warrant to Purchase Series B Preferred Stock is \$69.00 per share of Series B Preferred Stock. The exercise price is reported on an "as converted" basis after giving effect to the 5.926613 conversion ratio.
- The shares are owned by OVP VI Entrepreneurs Fund, L.P. ("OVP VI Entrepreneurs"). OVMC VI LLC serves as the general partner of OVP VI Entrepreneurs. Charles P. Waite, Jr. is a managing member of OVMC VI LLC and shares voting and investment power over the shares held by OVP VI Entrepreneurs. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
- (9) The warrant is immediately exercisable.

Remarks:

Form 2 of 2

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 5